anticancer agentsprotein kinase inhibitors

Aug 26, 2011

480 likes | 854 Views

Protein Kinases. Enzymes that catalyse phosphorylation reactions on protein substrates500-2000 estimated protein kinases in a cellProtein kinases are present in the cytoplasmProtein kinase receptors - dual role as receptor and enzymeOverexpression can result in cancerTyrosine kinases, serine-threonine kinases and histidine kinasesATP used as enzyme cofactor - phosphorylating agent.

Share Presentation

Embed Code

Link

ostinmannual

Download Presentation

anticancer agentsprotein kinase inhibitors

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Leukemia Therapy: Bcr-Abl Kinase Inhibitors: Selective vs Nonselective

THOMSON REUTERS INTEGRITY SM Leukemia Therapy: Bcr-Abl Kinase Inhibitors: Selective vs Nonselective THOMSON REUTERS INTEGRITY: SUMMARY In this use case, active compounds for Leukemia will be found and filtered by mechanisms of action and organization.

900 views • 27 slides

Anticancer therapy: Histone Deacetylase Inhibitors

Anticancer therapy: Histone Deacetylase Inhibitors. Afsha Rais. Histones are so cool!. In chromatins, DNA is wrapped around proteins of which most are histones. Histones assist in DNA packaging and have a regulatory role.

1.49k views • 22 slides

Leukemia Therapy: Bcr-Abl Kinase Inhibitors: Selective vs Nonselective

THOMSON REUTERS INTEGRITY SM. Leukemia Therapy: Bcr-Abl Kinase Inhibitors: Selective vs Nonselective. THOMSON REUTERS INTEGRITY: SUMMARY. In this use case, active compounds for Leukemia will be found and filtered by mechanisms of action and organization.

453 views • 27 slides

Anticancer Therapy: Kinase Inhibitors

Anticancer Therapy: Kinase Inhibitors. Charles Harrell. Outline of Material Presented. Definition of Cancer Understanding Kinases Kinase Inhibitor Functionality Economic Considerations Assigned Reading Homework Questions. What is Cancer?.

477 views • 20 slides

Bisphosphonic Acids Designed as Polyphosphate Kinase 2 Inhibitors

Bisphosphonic Acids Designed as Polyphosphate Kinase 2 Inhibitors. Małgorzata Burda , a Bogusław Nocek, b Artur Mucha, a Łukasz Berlicki a a Department of Bioorganic Chemistry, Faculty of Chemistry, Wrocław University of Technology

354 views • 17 slides

Primer on Kinase Inhibitors

Primer on Kinase Inhibitors. Richard R. Furman Directory, CLL Research Center Weill Cornell Medical College / New York Presbyterian Hospital. BCR-associated Kinases: Proven Effective Therapeutic Targets. Syk (spleen tyrosine kinase): R406, PRT062070.

828 views • 34 slides

Discontinuation of second generation tyrosine kinase inhibitors

Discontinuation of second generation tyrosine kinase inhibitors. Dr Delphine Rea Service des Maladies du Sang Hôpital Saint-Louis Paris, France Fi-LMC (France Intergroupe-Leucémies Myéloïdes Chroniques). CML and MPDs UK national meeting Newcastle, March 1 st , 2013.

493 views • 17 slides

Tyrosine Kinase Inhibitors in non-small cell lung cancer

Giuseppe Giaccone, MD PhD Chief, Medical Oncology Branch and Affiliated Branches. Tyrosine Kinase Inhibitors in non-small cell lung cancer. Estimated Cancer Death Rates in the United States 2009 Men 292,540; Women 269,800. Lung and bronchus 30% Prostate 9% Colon and rectum 9% Pancreas 6%

1.96k views • 97 slides

ANTICANCER AGENTS FARNESYL TRANSFERASE INHIBITORS

ANTICANCER AGENTS FARNESYL TRANSFERASE INHIBITORS. Chapter 21. Ras Protein. Notes Signalling protein that is crucial to cell growth and division Abnormal form is present in 30% of cancers Prevalent in colonic and pancreatic cancers Abnormal Ras is coded by a mutated ras gene

650 views • 22 slides

Therapeutic Drug Monitoring (TDM) of Tyrosine Kinase Inhibitors (TKI) in MRCC

Therapeutic Drug Monitoring (TDM) of Tyrosine Kinase Inhibitors (TKI) in MRCC. Réunion GSO Uro 19 Février 2014. TDM “Therapeutic Drug Monitoring”. Determination of plasma concentrations as a “routine” practice in order to adapt the individual dose Prerequisite of TDM :

706 views • 30 slides

Tyrosine Kinase inhibitors

Tyrosine Kinase inhibitors. Presented BY : Group 5, PharmD . Supervised by : Dr. Nashaat. Imatinib resistance. Resistance to imatinib is still a problem ,mainly in patients in the accelerated Or blast crisis phases of the disease.

1.52k views • 12 slides

Update on the Side Effects of Tyrosine Kinase Inhibitors

Update on the Side Effects of Tyrosine Kinase Inhibitors. Dr Jenny Byrne Nottingham University Hospitals Trust. IRIS Study: Most Frequently Reported AEs. Imatinib is a Safe Drug. Only Serious Adverse Events (SAEs) were collected after 2005

985 views • 28 slides

FDA Evaluation of Hepatotoxicity Related to Tyrosine Kinase Inhibitors

FDA Evaluation of Hepatotoxicity Related to Tyrosine Kinase Inhibitors. J Chang, 1 M Rand, 2 G Blumenthal, 1 P Cortazar, 1 C Kulick, 2 E Hausman, 2 S Chang, 2 R Pratt, 2 B Habtemariam, 3 Y Chen, 3 J Bullock, 3 RC Orbach, 3 I Zineh, 3 R Justice, 1 R Pazdur 4.

343 views • 14 slides

ANTICANCER AGENTS PROTEIN KINASE INHIBITORS

ANTICANCER AGENTS PROTEIN KINASE INHIBITORS. Chapter 21. Protein Kinases. Enzymes that catalyse phosphorylation reactions on protein substrates 500-2000 estimated protein kinases in a cell Protein kinases are present in the cytoplasm

1.99k views • 48 slides

Kinase Inhibitors in B-cell Lymphomas: What Does the Future Hold?

Kinase Inhibitors in B-cell Lymphomas: What Does the Future Hold?. Peter Martin, MD. Bruton ’ s Tyrosine Kinase (BTK) A critical kinase for lymphoma cell survival and proliferation. BTK is expressed and functional across non-T-cell hematopoietic lineages

740 views • 49 slides

Total Synthesis and Rational Design of Protein Kinase Inhibitors

Total Synthesis and Rational Design of Protein Kinase Inhibitors. Matthew Noestheden 1 st Seminar Thursday, February 16 th , 2006. Outline. What are protein kinases? Why are they important to study? Total synthesis of Wortmannin Rational design - purine scaffold

862 views • 60 slides

Recent progress of targeted kinase inhibitors in thyroid cancer

Recent progress of targeted kinase inhibitors in thyroid cancer. A/Prof Rory Clifton-Bligh Kolling Institute of Medical Research, University of Sydney Department of Endocrinology Royal North Shore Hospital, St Leonards, NSW. Royal North Shore Hospital.

665 views • 42 slides

Protein Kinase Inhibitors Market Applications, Trends and Dynamics Forecast to 2025

Protein kinase inhibitor industry is driven by factor such as rising R&D activities against cancer in developed countries. Additionally, technological innovations and data-driven customizations to fulfill consumer demand for efficiency and accurate outcome also propel the market growth in the forecast period.

98 views • 4 slides

Second and Third Generation Tyrosine Kinase Inhibitors: How do we Choose?

Second and Third Generation Tyrosine Kinase Inhibitors: How do we Choose?. Dr Jenny Byrne Nottingham. Imatinib is a wonderful drug !. 1. 0. 0. 9. 0. 8. 0. 7. 0. i. Es. t. imaa. t. e. d. o. v. e. r. a. l. l. s. u. r. ivaa. i. l. m. l. 6. 0. a. t. 8. y. e.

383 views • 36 slides

Tyrosine Kinase Inhibitors PHL 425

Tyrosine Kinase Inhibitors PHL 425. Dr. Mohamed M. Sayed-AShmed. Tyrosine Kinases. There are 2 major classes of tyrosine kinases.

226 views • 16 slides

Tyrosine Kinase Inhibitors PHL 417

Tyrosine Kinase Inhibitors PHL 417. Tyrosine Kinases. There are 2 major classes of tyrosine kinases.

196 views • 17 slides

Dual Specificity Protein Kinase TTK Inhibitors Market: Emerging Opportunities

The Dual Specificity Protein Kinase TTK (TTK) is a critical enzyme involved in cell division and mitosis. TTK inhibitors are a class of pharmaceutical compounds designed to target and inhibit the activity of TTK, thereby disrupting cell division and suppressing the growth of cancer cells. These inhibitors have shown promising potential in the field of oncology, leading to a growing interest in the Dual Specificity Protein Kinase TTK Inhibitors market.

35 views • 3 slides

More Related